139 related articles for article (PubMed ID: 38382919)
1. Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer - author's reply.
Hong H; Choi J
Clin Mol Hepatol; 2024 Apr; 30(2):272-273. PubMed ID: 38382919
[No Abstract] [Full Text] [Related]
2. Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer.
Cheng PN; Yu ML
Clin Mol Hepatol; 2024 Apr; 30(2):144-146. PubMed ID: 38373418
[No Abstract] [Full Text] [Related]
3. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Chan HL; Fung S; Seto WK; Chuang WL; Chen CY; Kim HJ; Hui AJ; Janssen HL; Chowdhury A; Tsang TY; Mehta R; Gane E; Flaherty JF; Massetto B; Gaggar A; Kitrinos KM; Lin L; Subramanian GM; McHutchison JG; Lim YS; Acharya SK; Agarwal K;
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):185-195. PubMed ID: 28404091
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Buti M; Gane E; Seto WK; Chan HL; Chuang WL; Stepanova T; Hui AJ; Lim YS; Mehta R; Janssen HL; Acharya SK; Flaherty JF; Massetto B; Cathcart AL; Kim K; Gaggar A; Subramanian GM; McHutchison JG; Pan CQ; Brunetto M; Izumi N; Marcellin P;
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):196-206. PubMed ID: 28404092
[TBL] [Abstract][Full Text] [Related]
5. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
Lampertico P; Buti M; Fung S; Ahn SH; Chuang WL; Tak WY; Ramji A; Chen CY; Tam E; Bae H; Ma X; Flaherty JF; Gaggar A; Lau A; Liu Y; Wu G; Suri V; Tan SK; Subramanian GM; Trinh H; Yoon SK; Agarwal K; Lim YS; Chan HLY
Lancet Gastroenterol Hepatol; 2020 May; 5(5):441-453. PubMed ID: 32087795
[TBL] [Abstract][Full Text] [Related]
6. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.
Agarwal K; Fung SK; Nguyen TT; Cheng W; Sicard E; Ryder SD; Flaherty JF; Lawson E; Zhao S; Subramanian GM; McHutchison JG; Gane EJ; Foster GR
J Hepatol; 2015 Mar; 62(3):533-40. PubMed ID: 25450717
[TBL] [Abstract][Full Text] [Related]
7. Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic hepatitis B patients-author's reply.
Papatheodoridis GV
Aliment Pharmacol Ther; 2022 Sep; 56(5):918-919. PubMed ID: 35934846
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.
Li B; Liu Z; Liu X; Liu D; Duan M; Gu Y; Liu Q; Ma Q; Wei Y; Wang Y
Hepatol Int; 2021 Oct; 15(5):1103-1108. PubMed ID: 34312798
[TBL] [Abstract][Full Text] [Related]
9. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
Liu Z; Zhao Z; Ma X; Liu S; Xin Y
BMC Gastroenterol; 2023 Nov; 23(1):384. PubMed ID: 37950196
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.
Hsu YC; Wei MT; Nguyen MH
Expert Rev Gastroenterol Hepatol; 2017 Nov; 11(11):999-1008. PubMed ID: 28965428
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide.
Hong H; Choi WM; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Choi J
Clin Mol Hepatol; 2024 Jan; 30(1):49-63. PubMed ID: 37981763
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.
Gallant JE; Daar ES; Raffi F; Brinson C; Ruane P; DeJesus E; Johnson M; Clumeck N; Osiyemi O; Ward D; Morales-Ramirez J; Yan M; Abram ME; Plummer A; Cheng AK; Rhee MS
Lancet HIV; 2016 Apr; 3(4):e158-65. PubMed ID: 27036991
[TBL] [Abstract][Full Text] [Related]
13. [Research progress on the effect of tenofovir disoproxil fumarate on blood lipid profile].
Duan YQ; Hu P
Zhonghua Gan Zang Bing Za Zhi; 2023 Oct; 31(10):1103-1107. PubMed ID: 38016781
[TBL] [Abstract][Full Text] [Related]
14. Switching from Tenofovir Disoproxil to Tenofovir Alafenamide Fumarate: Impact on Cardiovascular Risk and Lipid Profile in People Living with HIV, an Observational Study.
Moschopoulos CD; Protopapas K; Thomas K; Kavatha D; Papadopoulos A; Antoniadou A
AIDS Res Hum Retroviruses; 2023 Feb; 39(2):68-75. PubMed ID: 36401506
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis.
Funk AL; Lu Y; Yoshida K; Zhao T; Boucheron P; van Holten J; Chou R; Bulterys M; Shimakawa Y
Lancet Infect Dis; 2021 Jan; 21(1):70-84. PubMed ID: 32805200
[TBL] [Abstract][Full Text] [Related]
16. Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B can increase body weight-Authors' reply.
Ogawa E
Aliment Pharmacol Ther; 2024 Apr; 59(7):909-910. PubMed ID: 38462688
[No Abstract] [Full Text] [Related]
17. Tenofovir disoproxil fumarate for the treatment of hepatitis B infection.
Adusumilli S
Drugs Today (Barc); 2009 Sep; 45(9):679-85. PubMed ID: 19956809
[TBL] [Abstract][Full Text] [Related]
18. Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles.
Lin HY; Tseng TC
Clin Mol Hepatol; 2022 Apr; 28(2):181-182. PubMed ID: 35184513
[No Abstract] [Full Text] [Related]
19. No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection.
Cathcart AL; Chan HL; Bhardwaj N; Liu Y; Marcellin P; Pan CQ; Shalimar ; Buti M; Cox S; Parhy B; Zhou E; Martin R; Chang S; Lin L; Flaherty JF; Kitrinos KM; Gaggar A; Izumi N; Lim YS
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30038044
[TBL] [Abstract][Full Text] [Related]
20. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
Li J; Hu C; Chen Y; Zhang R; Fu S; Zhou M; Gao Z; Fu M; Yan T; Yang Y; Li J; Liu J; Chen T; Zhao Y; He Y
BMC Infect Dis; 2021 Jun; 21(1):567. PubMed ID: 34126939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
